BLU-667 Targets RET-Altered Cancers [News in Brief]

Investigational drug is safe, shows early promise in patients with medullary thyroid cancer and NSCLC.

from Cancer via ola Kala on Inoreader https://ift.tt/2HEk9Y4
via IFTTT